Ashlins Calls Interferon Alpha-2b De-Risked; FDA Evidence Gap Remains

Ashlins Pharmaceuticals has licensed ex-China rights to develop products using Lee’s Pharm’s interferon alpha-2b API in a deal worth up to $31 million. The rare disease startup now plans to raise about $50 million and believes the funding could take